Ignite Creation Date:
2024-05-06 @ 4:10 PM
Last Modification Date:
2024-10-26 @ 2:05 PM
Study NCT ID:
NCT04897997
Status:
UNKNOWN
Last Update Posted:
2021-05-24
First Post:
2021-05-04
Brief Title:
Effect of Smoking on Activated Clotting Time Values During Coronarography and Angioplasty
Sponsor:
Central Hospital Nancy France
Organization:
Central Hospital Nancy France
Study Overview
Official Title:
Effect of Smoking on Activated Clotting Time Values During Coronary Angioplasty
Status:
UNKNOWN
Status Verified Date:
2021-05
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
analyzing influence of smoking on patients anti-coagulation status as assessed by ACT measurements during coronary angioplasty
Detailed Description:
During angioplasty activated clotting time ACT measurements are recommended to attest the correct anticoagulation level and if anticoagulation levels are suboptimal after the two first boluses additional unfractionated heparin UFH injections are recommended until obtention of a therapeutic ACT values 250-350s
The study hypothesis was that the procoagulant effect of the tobacco may be responsible of reduced anticoagulation levels after standardized UFH administrations and thus presenting an UFH resistance requiring increased UFH dosages to obtain a therapeutic ACT values
The study hypothesis was that the procoagulant effect of the tobacco may be responsible of reduced anticoagulation levels after standardized UFH administrations and thus presenting an UFH resistance requiring increased UFH dosages to obtain a therapeutic ACT values
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None